Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel

Blood ◽  
2010 ◽  
Vol 116 (16) ◽  
pp. 2875-2883 ◽  
Author(s):  
Vito Di Marco ◽  
Marcello Capra ◽  
Emanuele Angelucci ◽  
Caterina Borgna-Pignatti ◽  
Paul Telfer ◽  
...  

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical management of chronic liver disease in thalassemia patients is a team management issue requiring a multidisciplinary approach. The purposes of this paper are to summarize the knowledge on the epidemiology and the risks of transmission of viral infections, to analyze invasive and noninvasive methods for the diagnosis of chronic liver disease, to report the knowledge on clinical course of chronic viral hepatitis, and to suggest the management of antiviral therapy in thalassemia patients with chronic hepatitis B or C virus or cirrhosis.

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Gaetano Bertino ◽  
Annalisa Maria Ardiri ◽  
Giuseppe Stefano Calvagno ◽  
Giulia Malaguarnera ◽  
Donatella Interlandi ◽  
...  

Background.Carbohydrate 19.9 antigen (CA19.9) has been used in the diagnosis and followup of gastrointestinal tumours. The aim of this prospective longitudinal study was the evaluation of CA19.9 levels in patients with chronic hepatitis and hepatic cirrhosis hepatitis C virus and B virus correlated.Materials and Methods. 180 patients were enrolled, 116 with HCV-related chronic liver disease (48% chronic hepatitis, 52% cirrhosis) and 64 with HBV-related chronic liver disease (86% chronic hepatitis, 14% cirrhosis). Patients with high levels of CA19.9 underwent abdominal ecography, gastroendoscopy, colonoscopy, and abdominal CT scan.Results.51.7% of patients with HCV-related chronic liver disease and 48.4% of those with HBV-related chronic liver disease presented high levels of CA19.9. None was affected by pancreatic or intestinal neoplasia, cholestatic jaundice, or other diseases potentially able to induce Ca19.9 elevations. CA19.9 levels were elevated in 43.3% of HCV chronic hepatitis, in 56.3% of HCV cirrhosis, in 45.1% of HBV chronic hepatitis, and in 58% of HBV cirrhosis.Conclusions.CA19.9 commonly increases in the serum of patients with chronic viral hepatitis. Elevation of CA 19.9 is not specific for neoplastic disease and is related to the severity of fibrosis and to the viral aetiology of hepatitis.


Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1576 ◽  
Author(s):  
Daisuke Uchida ◽  
Akinobu Takaki ◽  
Atsushi Oyama ◽  
Takuya Adachi ◽  
Nozomu Wada ◽  
...  

Chronic viral hepatitis B and C and non-alcoholic fatty liver disease (NAFLD) have been widely acknowledged to be the leading causes of liver cirrhosis and hepatocellular carcinoma. As anti-viral treatment progresses, the impact of NAFLD is increasing. NAFLD can coexist with chronic viral hepatitis and exacerbate its progression. Oxidative stress has been recognized as a chronic liver disease progression-related and cancer-initiating stress response. However, there are still many unresolved issues concerning oxidative stress, such as the correlation between the natural history of the disease and promising treatment protocols. Recent findings indicate that oxidative stress is also an anti-cancer response that is necessary to kill cancer cells. Oxidative stress might therefore be a cancer-initiating response that should be down regulated in the pre-cancerous stage in patients with risk factors for cancer, while it is an anti-cancer cell response that should not be down regulated in the post-cancerous stage, especially in patients using anti-cancer agents. Antioxidant nutrients should be administered carefully according to the patients’ disease status. In this review, we will highlight these paradoxical effects of oxidative stress in chronic liver diseases, pre- and post-carcinogenesis.


2019 ◽  
Vol 11 (4) ◽  
pp. 189-191
Author(s):  
Amir Anushiravani ◽  
Sadaf Ghajarieh Sepanlou

There has been an increase in the burden of liver diseases in Iran, with an increasing trend from communicable to non-communicable diseases. Almost 5400 deaths were due to chronic liver diseases in 2017. We aim to provide a concise update on the epidemiological trends of liver diseases in Iran. Estimations of deaths, disability-adjusted life years, prevalence of chronic liver diseases and cirrhosis in Iran with its common etiologies have been reported. We investigated the major causes of chronic liver diseases in Iran, we have reported our hepatology research centers, and also we have depicted the future of liver diseases in Iran. In 2017, there was a rising trend in chronic liver diseases in Iran. The most common etiologies for chronic liver disease were chronic hepatitis B, chronic hepatitis C, and non-alcoholic steatohepatitis with highest mortalities due to liver cancer and hepatitis C. The prevalence of HBV infection has decreased from 2.9% to 1.3% with effective vaccination, but new cases are still seen due to perinatal transmission. Treatment of HCV has dramatically changed with new drugs which are being produced by local pharmaceuticals at a low cost. The main obstacle in its elimination is finding patients and linkage to care. More than a third of our population have non-alcoholic fatty liver disease in which central obesity had a stronger association than weight itself. Iran has a high burden of liver diseases. The Ministry of Health has effectively controlled hepatitis B and is working towards the World Health WHO’s goals for hepatitis C by 2030. This being said, non-alcoholic fatty liver disease is becoming a major threat to our nation’s health and quality of life.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5567-5567 ◽  
Author(s):  
Mashrafi Ahmed ◽  
Fawwad Zaidi ◽  
Tahmina Begum ◽  
Ashok R. Patel

Abstract Introduction: Cirrhosis of liver due to chronic hepatitis B and/or C is a significant health care burden globally. Thrombocytopenia is one of the significant co-morbid conditions associated with cirrhosis. Splenomegaly had been pointed as one of the main factors behind thrombocytopenia in multiple studies. Another important aspect of this clinical condition is its high economic impact in the national health care budget. In this study, we re-evaluated the relation between thrombocytopenia, MELD score and spleen size in liver cirrhosis associated with chronic hepatitis B and/or C. We also evaluated the impact of these 3 factors over readmission of the patients at 30 and 90 days. Method: In this retrospective study, the medical records of patients admitted to Saint Joseph Hospital, Chicago, IL between January 1st, 2005 and December 31st, 2010 were queried for a discharge diagnosis of Chronic liver disease due to Hepatitis B and/or C. Result: Data Summary To examine the relationship between the biomarkers, scatter plot was generated for visual inspection. There was no apparent relationship between platelet count and MELD or spleen size. Correlation analysis by Spearman method showed a weak negative correlation between platelet count and MELD score (P=0.0051, coefficient = -0.26). To predict the probability of re-admission by the biomarkers, logistic regression was used to select significant predictors. From univariate analysis, only MELD was a significant predictor in 30-day re-admission (P=0.012, AUC=0.665). For 90-day re-admission, both MELD (P=0.0034, AUC=0.691) and platelet count (P=0.030, AUC=0.647) were significant predictors in univariate analysis. Summary In this study, all subjects have chronic liver disease due to viral infection. Platelet count is not related to MELD score or spleen size in these hepatitis B, C, or B/C patients. The combination of MELD, platelet count, and spleen size fairly predicts 30-day re-admission occurrence with an AUC of 0.726. Discussion: Thrombocytopenia is a common hematological complication in patient with chronic liver disease. The mechanism of thrombocytopenia classically is thought to be caused by pooling and destruction of platelets within the enlarged spleen. Other proposed mechanisms are impaired platelet production in the bone marrow, production of inhibitors of platelet production in the spleen, and decreased platelet growth factor thrombopoietin production from liver as well as increased degradation of thrombopoietin by platelets sequestered in the congested spleen. A recent study showed that in more severe chronic hepatitis due to hepatitis-c virus where severity was assessed with Child-Pugh score, both mature and premature platelet counts are low and this inverse relation also correlates with platelet growth factor thrombopoietin level which is low in more severe liver disease. Since Child-Pugh scoring system has some degree of limitation due to subjective variation, we decided to use MELD score for our patients to assess the severity of the chronic liver disease. Our study interestingly showed no correlation between platelet count, MELD score and spleen size. Study revealed only MELD was a significant predictor in 30-day re-admission (P=0.012, AUC=0.665). For 90-day re-admission, both MELD (P=0.0034, AUC=0.691) and platelet count (P=0.030, AUC=0.647) No correlation was observed even when cohorts were broken down into separately for male and female, for patients below and above 62 years old (the median age), and for each hepatitis subtype. 30-day re admission was clearly not related Platelet count or spleen alone but in combination they were linearly related to 30 and 90 day readmission. This study was important for multiple reasons. Firstly, 30 day readmission was calculated to be 16% and 90 day readmission was found to be 29% including the 16% from 30-day readmission. Surprisingly MELD alone was not a good predictor for 30 day readmission, but in combination with other parameters Spleen size and platelet count, predictions were fairly accurate. Table 1. Statistical Analysis and Results Table 1. Statistical Analysis and Results Figure 1. ROC of 30-day re-admission. Figure 1. ROC of 30-day re-admission. Figure 2. ROC of 90-day re-admission. Figure 2. ROC of 90-day re-admission. Disclosures No relevant conflicts of interest to declare.


2012 ◽  
Vol 32 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Marketa Dostalikova-Cimburova ◽  
Karolina Kratka ◽  
Jaroslav Stransky ◽  
Ivana Putova ◽  
Blanka Cieslarova ◽  
...  

The aim of the study was to identify the prevalence ofHFEgene mutations in Czech patients with chronic liver diseases and the influence of the mutations on iron status. The presence ofHFEgene mutations (C282Y, H63D, and S65C) analyzed by the PCR-RFLP method, presence of cirrhosis, and serum iron indices were compared among 454 patients with different chronic liver diseases (51 with chronic hepatitis B, 122 with chronic hepatitis C, 218 with alcoholic liver disease, and 63 patients with hemochromatosis). Chronic liver diseases patients other than hemochromatics did not have an increased frequency ofHFEgene mutations compared to controls. Although 33.3% of patients with hepatitis B, 43% of patients with hepatitis C, and 73.2% of patients with alcoholic liver disease had elevated transferrin saturation or serum ferritin levels, the presence ofHFEgene mutations was not significantly associated with iron overload in these patients. Additionally, patients with cirrhosis did not have frequencies ofHFEmutations different from those without cirrhosis. This study emphasizes the importance, not only of C282Y, but also of the H63D homozygous genetic constellation in Czech hemochromatosis patients. Our findings show that increased iron indices are common in chronic liver diseases butHFEmutations do not play an important role in the pathogenesis of chronic hepatitis B, chronic hepatitis C, and alcoholic liver disease.


Gut ◽  
1998 ◽  
Vol 42 (1) ◽  
pp. 107-111 ◽  
Author(s):  
M Guilera ◽  
J C Sáiz ◽  
F X López-Labrador ◽  
E Olmedo ◽  
S Ampurdanés ◽  
...  

Background—The hepatitis G virus (HGV), a recently identified member of the Flaviviridae family, can cause chronic infection in man but the role of this agent in chronic liver disease is poorly understood.Aims—To evaluate the prevalence and meaning of HGV infection in a large series of patients with chronic liver disease.Subjects—Two hundred volunteer blood donors, 179 patients with chronic hepatitis C, 111 with chronic hepatitis B, 104 with alcoholic liver disease, 136 with hepatocellular carcinoma, and 24 with cryptogenic chronic liver disease were studied.Methods—HGV RNA was investigated in serum samples by reverse transcription and polymerase chain reaction amplification of the 5′ non-coding region of HCV and hybridisation to a specific probe. The main features of HGV RNA seropositive and seronegative patients were compared.Results—The prevalence of HGV infection was 3% in blood donors, 7% in chronic hepatitis C, 8% in chronic hepatitis B, 2% in alcoholic liver disease, 4% in hepatocellular carcinoma, and 8% in cryptogenic chronic liver disease. HGV infected patients tended to be younger than non-infected patients but no differences concerning sex, possible source of infection, clinical manifestations, biochemical and virological parameters, or severity of liver lesions were found.Conclusions—The prevalence of HGV infection in chronic liver disease seems to be relatively low in our area. Infection with HGV does not seem to play a significant pathogenic role in patients with chronic liver disease related to chronic HBV or HCV infection or to increased alcohol consumption, or in those with cryptogenic chronic liver disease.


Sign in / Sign up

Export Citation Format

Share Document